y90 monoclonal antibody mn-14
mAbexperimentalADC
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 1997 (NCT00004087)
Timeline
1990s
- Jan 1, 1997
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Also known as
- y90 monoclonal antibody mn-14
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00006347 | Phase 1 | Aug 1, 2000 | Garden State Cancer Center, National Cancer Institute (NCI) |
| NCT00006458 | Phase 1 | Aug 1, 2000 | Garden State Cancer Center, National Cancer Institute (NCI) |
| NCT00004177 | Phase 1/Phase 2 (Phase 2) | Aug 1, 1999 | Garden State Cancer Center, National Cancer Institute (NCI) |
| NCT00004048 | Phase 1/Phase 2 (Phase 2) | Sep 1, 1998 | Garden State Cancer Center |
| NCT00004085 | Phase 1/Phase 2 (Phase 2) | May 1, 1998 | Garden State Cancer Center, National Cancer Institute (NCI) |
| NCT00004087 | Phase 1/Phase 2 (Phase 2) | Mar 1, 1997 | Garden State Cancer Center, National Cancer Institute (NCI) |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Garden State Cancer Center | Academic/Hospital | 6 | 6 | 2 | 1997 |
| National Cancer Institute (NCI) | Government | 5 | 0 | 2 | 1997 |
2 organizations
Page 1 / 1